Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

BeOne Medicines (BEIGF) FCF Margin (2016 - 2025)

Historic FCF Margin for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to 25.1%.

  • BeOne Medicines' FCF Margin rose 196400.0% to 25.1% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.95%, marking a year-over-year increase of 409400.0%. This contributed to the annual value of 16.62% for FY2024, which is 533100.0% up from last year.
  • BeOne Medicines' FCF Margin amounted to 25.1% in Q3 2025, which was up 196400.0% from 16.98% recorded in Q2 2025.
  • BeOne Medicines' FCF Margin's 5-year high stood at 25.1% during Q3 2025, with a 5-year trough of 305.88% in Q2 2021.
  • For the 5-year period, BeOne Medicines' FCF Margin averaged around 74.7%, with its median value being 59.68% (2023).
  • Per our database at Business Quant, BeOne Medicines' FCF Margin skyrocketed by 7212200bps in 2021 and then crashed by -1213000bps in 2022.
  • Over the past 5 years, BeOne Medicines' FCF Margin (Quarter) stood at 5.66% in 2021, then tumbled by -2143bps to 115.64% in 2022, then skyrocketed by 48bps to 59.68% in 2023, then skyrocketed by 97bps to 1.54% in 2024, then skyrocketed by 1734bps to 25.1% in 2025.
  • Its FCF Margin was 25.1% in Q3 2025, compared to 16.98% in Q2 2025 and 1.43% in Q1 2025.